Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
- Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
- Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05664880
- Locations
- 🇺🇸
Marissa Podell, Los Angeles, California, United States
A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT04994080
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 15
- Registration Number
- NCT04617067
- Locations
- 🇮🇪
University Hospital Waterford, Waterford, Ireland
🇮🇪Tallaght University Hospital, Dublin, Dublin 24, Ireland
🇮🇪St. Vincent's University Hospital, Dublin, Dublin 4, Ireland
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT04524702
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hosptial, Atlanta, Georgia, United States
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 16
- Registration Number
- NCT04064827
- Locations
- 🇺🇸
Seattle Children's Hospital /ID# 162861, Seattle, Washington, United States
🇺🇸Boston Children's Hospital /ID# 162863, Boston, Massachusetts, United States
🇺🇸Duplicate_Levine Children's Specialty Center- Charlotte /ID# 216057, Charlotte, North Carolina, United States
Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Barts & The London NHS Trust
- Target Recruit Count
- 14
- Registration Number
- NCT04054362
- Locations
- 🇬🇧
Barts Health NHS Trust, London, London, Greater, United Kingdom
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT03883919
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT03520790
- Locations
- 🇺🇸
Penn Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT03519308
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Translational Genomics Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT03331562
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.